Bio-Path Holdings, Inc. announced positive developments in its ongoing clinical trials, including the Phase 1/1b trial of BP1001-A for solid tumors and a Phase 2 study of prexigebersen in Acute ...
The report assessed the progress made by member states on implementing the recommendations in the 2024 report, finding that 57 per cent of them have been followed up, either fully or partially.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback